{‘She has zero qualifications’: this American medical field prepares for Tracy Beth Høeg’s appointment at the Food and Drug Administration.

While America continues making unprecedented changes to its vaccine recommendations, a particular individual has emerged unexpectedly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning coronavirus vaccinations throughout the pandemic and has focused upon alleged deaths following COVID-19 immunization in her brief tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Program

Agency leaders had intended to reveal sweeping revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US at odds with a large portion of the world with no evidence for benefit. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A Shift at the Agency

This interim role may indicate a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

Høeg has repeatedly called for discontinuing some childhood immunization guidelines in the US in order to be more like Denmark, a society with nationalized medicine and a population about the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has little discernible track record in medication creation, regulation or management, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a large organization. She is not an expert in pharmaceutical oversight.”

Past commissioners of the center would “understand laws and regulations and the underlying principles of drug development”, commented Janet Woodcock. “Objectively, she lacks the type of experience that previous people who headed the center have had.”

This division has an immense portfolio at the FDA, Woodcock emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division clears thousands of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and all of those must be supervised,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a major administrative element to the position, which oversees over 5,000 personnel. “It is a massive leadership role, if you execute it properly,” Woodcock added.

Official Statement and Disputed Programs

Regarding questions about Høeg’s qualifications and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a representative responded that the “inquiries are based on inaccurate assumptions”.

“Her experience is consistent with the functions of her role,” the representative said, noting the period Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed one-day therapy clearance system that apparently concerned her preceding directors. “How are these medications being picked for this fast-track system? Who takes the choices?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he said, “the agency seems to be moving towards laxer oversight of pharmaceuticals, with the exception of shots.”

Established Past Work on Immunizations

Regarding vaccines, Høeg has a clearer, if troubling, track record, some experts said. She released a research paper using non-validated public submissions to assess the incidence of myocarditis following COVID-19 immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the new government encompassed altering rules for new vaccines and halting “optional” immunizations, she remarked following the vote on a online show. At the FDA, Høeg has allegedly floated the idea of barring adolescent males from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a extremely disingenuous, dishonest way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined other dissenters, {like|